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Background: Soluble fragments of the amyloid precursor protein (APP) generated by α- and β-secretases, sAPPα
and sAPPβ, have been postulated as promising new cerebrospinal fluid (CSF) biomarkers for the clinical diagnosis of
Alzheimer’s disease (AD). However, the capacity of these soluble proteins to assemble has not been explored and
could be relevant. Our aim is to characterize possible sAPP oligomers that could contribute to the quantification of
sAPPα and sAPPβ in CSF by ELISA, as well as to characterize the possible presence of soluble full-length APP
(sAPPf).
Results: We employed co-immunoprecipitation, native polyacrylamide gel electrophoresis and ultracentrifugation in
sucrose density gradients to characterize sAPP oligomers in CSF. We have characterized the presence of sAPPf in CSF
from NDC and AD subjects and demonstrated that all forms, including sAPPα and sAPPβ, are capable of assembling
into heteromers, which differ from brain APP membrane-dimers. We measured sAPPf, sAPPα and sAPPβ by ELISA in
CSF samples from AD (n = 13) and non-disease subjects (NDC, n = 13) before and after immunoprecipitation with
antibodies against the C-terminal APP or against sAPPβ. We demonstrated that these sAPP heteromers participate
in the quantification of sAPPα and sAPPβ by ELISA. Immunoprecipitation with a C-terminal antibody to remove
sAPPf reduced by ~30% the determinations of sAPPα and sAPPβ by ELISA, whereas immunoprecipitation with an
APPβ antibody reduced by ~80% the determination of sAPPf and sAPPα.
Conclusions: The presence of sAPPf and sAPP heteromers should be taken into consideration when exploring
the levels of sAPPα and sAPPβ as potential CSF biomarkers.
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Abnormal accumulation of β-amyloid peptide (Aβ) in
the brain is characteristic of Alzheimer’s disease (AD).
The Aβ peptide is generated by processing a large type
I transmembrane spanning glycoprotein, the amyloid
precursor protein (APP), through the successive action
of proteolytic enzymes called secretases. Sequential
processing of APP begins with either the action of α-
secretase, or alternatively by β-secretase, followed by γ-
secretase cleavage ([1]; see also Figure 1A). When APP* Correspondence: j.saez@umh.es
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article, unless otherwise stated.molecules are cleaved by α-secretase within the Aβ do-
main, the generation of the Aβ peptide is precluded.
When cleavage is carried out by β and γ-secretase, a
17-43 amino acid Aβ peptide is generated [2]. The
Aβ40 peptide is the most abundant species, while the
Aβ42 variant is the most amyloidogenic form of the
peptide, associated with AD pathogenesis [3]. Cleavage
by α- and β-secretase also generates soluble forms of
APP, named sAPPα and sAPPβ, respectively, which are
present in human CSF [4,5] and have been postulated
as potential new AD biomarkers. However, to date, no
consistent change in CSF sAPPα and sAPPβ levels have
been identified as associated to the AD condition [6].
Moreover, an unexpected positive correlation has been
consistently reported between both forms, indicating a
similar shift for sAPPα and sAPPβ levels [7-10].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Soluble full-length APP (sAPPf) is present in human CSF. (A) Schematic representation of full-length APP processing by α/γ-secretase
(non-amyloidogenic pathway) and β/γ-secretase (amyloidogenic pathway) and the generation of extracellular large sAPPα, sAPPβ fragments, and the
shorter Aβ and p3 peptides; as well as fragments containing the C-terminal APP (CTF and ICD) (not drawn in scale). The epitopes for the
anti-APP antibodies used in this study are indicated. (B) Western blotting of human CSF samples from non-demented controls (NDC) subjects, resolved
with the indicated anti-APP antibodies. (C, D) CSF aliquots (Total, T) were immunoprecipitated with either the anti-C-terminal APP antibody from Sigma
(C, Sigma-Ct) or the pan-specific IBL-β antibody (D, IBL-β). Precipitated proteins (bound fraction, B) were immunoblotted with the antibodies
as indicated. In the absence of capture-antibody (IPc), no bands were observed.
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APP containing an intact cytoplasmic domain also exists
as a soluble form (sAPPf ) [11,12]. The possible contribu-
tion of sAPPf when estimating levels of large sAPP frag-
ments in CSF has thus far not been considered, nor has
the existence of APP heteromers [13] in CSF. The possi-
bility that sAPP exists in CSF forming oligomers is par-
ticularly relevant, since most quantifications of sAPPα
and sAPPβ in CSF from Alzheimer’s disease subjects rely
on ELISA determinations.
In this study, we investigate the presence of sAPPf in
AD CSF, as well as the oligomerization of sAPP spe-
cies, to determine how this may affect the measure-
ment of sAPPα/sAPPβ levels by currently available
ELISA immunoassays.
Results
sAPPf is present in CSF and forms heteromers
To determine the presence of sAPPf in human CSF, we
first examined samples by Western blotting using different
anti-APP antibodies (Figure 1A shows a schematic repre-
sentation of full-length APP, sAPP fragments generated
after secretases processing and the epitopes recognized
by different antibodies). The 6E10 antibody, which
recognizes an epitope present in sAPPα, and absent
in sAPPβ, revealed bands of approximately ~110 and
130 kDa (Figure 1B). A similar banding pattern wasobtained for sAPPβ using a pan-specific antibody for
the C-terminus of sAPPβ (IBL; Figure 1B). It is not possible
to distinguish between sAPPα and sAPPβ by Western blot-
ting due to their small size difference. Immunoblotting
with a C-terminal APP antibody (Covance-Ct) displayed
similar sAPP banding patterns, revealing a broad band
of ~110 kDa, and a faint band of 130 kDa only evident in
some samples (Figure 1B). An antibody against the N-
terminal (Sigma-Nt) also detected bands similar in size to
the immunoreactive bands detected with the previous anti-
bodies. The specificity of these antibodies was tested and
confirmed (see Additional file 1: Figure S1).
To further characterize sAPPf in human CSF, we per-
formed immunoprecipitation/Western blotting assays
(Figure 1C). CSF samples were immunoprecipitated using
a C-terminal APP antibody (Sigma-Ct) and detection was
performed with several antibodies. The 6E10 and Sigma-
Nt antibodies confirmed the specificity of the APP signal
in immunoprecipitates. The alternative C-terminal APP
antibody Covance-Ct confirmed the presence of sAPPf in
CSF samples (Figure 1C). The sAPPβ antibody specific for
its C-terminus (IBL-β) also recognized APP forms immu-
noprecipitated by the C-terminal APP antibody, suggest-
ing the presence of heteromers of sAPPf and sAPPβ
containing the C-terminal. To corroborate the presence of
these heteromers, CSF samples were immunoprecipitated
with IBL-β, and then immunoblotted with Sigma-Nt,
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blots with 6E10 and Covance-Ct demonstrated the pres-
ence of heteromers containing sAPPβ and sAPPf. Due to
6E10 also recognizes sAPPα, we do not discard the pres-
ence of heteromers containing sAPPβ and sAPPα. We do
not exclude that some of the 6E10 immunoreactivity de-
tected in Sigma-Ct immunoprecipitates arises from sAPPα
forms, reflecting the presence of heteromers containing
sAPPf and sAPPα. In the absence of capture-antibody
(IPc), or when a rabbit IgG was used for immunoprecipi-
tation (not shown), no bands were observed on the immu-
noblots (Figure 1C, D).Figure 2 Characterization of APP complexes by native-PAGE and sucro
(frontal cortex from NDC subjects) and CSF samples (NDC subjects) were
the different APP epitopes confirmed the presence of APP dimers in brain
complexes with higher molecular weight. A CSF sample denatured by bo
analyzed by blue native-PAGE to warrant the migration of the monomeric sAP
20% sucrose density gradients. The fractions (collected from the top of each tu
with IBL-β and Sigma-Ct antibodies for CSF samples. Enzymes of known sedim
~232 kDa) and alkaline phosphatase (P, 6.1S; ~140-160 kDa) were used as interNext, we characterized sAPP oligomers from brain
membranes and CSF samples by blue native-PAGE
(Figure 2A). Brain samples were solubilized in buffer
containing 0.5% dodecylmaltoside [14]. The major APP
band in the brain was identified at ~240 kDa with the
6E10 antibody. This molecular mass corresponds to the
predictable size of APP dimers. Weaker bands with
high molecular mass were also identified at ~480 and
720 kDa, probably corresponding to large complexes
formed by association of APP dimers. In CSF, the major
band is at ~240 kDa, with smear-like bands of higher
molecular mass also visible (Figure 2A), confirming thatse gradient ultracentrifugation. (A) APP complexes from the brain
analyzed by blue native-PAGE. Incubation of blots with antibodies for
extracts and CSF samples (~242 kDa), but also the existence of APP
iling at 95°C for 5 min under fully reducing conditions (Dn) was also
P band. (B) Brain extracts and CSF samples were also fractionated on 5-
be) were immunoblotted for APP with the 6E10 antibody, and additionally
entation coefficient, β-galactosidase (G, 16.0S; ~540 kDa), catalase (C, 11.4S;
nal markers.
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of results from blue native-PAGE analysis of membrane
protein complexes is complicated by the limitations in
comparing the determinations of molecular size with
the motilities of hydrophilic molecular weight markers.
To resolve this, we have included the resolution of a
CSF control sample denatured by boiling at 95°C for
5 min under fully reducing conditions and analyzed by
blue native-PAGE. This denatured CSF sample served
to locate the monomeric sAPP band and confirmed that
APP-immunoreactive bands resolved under native con-
ditions corresponded to dimers and high molecular
mass complexes. Similar APP-immunoreactive banding
patterns were identified in CSF with 6E10, IBL-β and
Covance-Ct antibodies.
Previous studies have employed gradient centrifuga-
tion to characterize APP complexes [12]. Sucrose dens-
ity gradients containing Brij 97 detergent were used to
characterize APP complexes from brain membrane
fractions and CSF samples (Figure 2B). The majority of
APP solubilized from the human brain in the presence
of dodecylmaltoside accumulated between catalase (C,
sedimentation coefficient 11.4 S, molecular weight
~232 kDa) and alkaline phosphatase markers (P, sedi-
mentation coefficient 6.1 S, molecular weight ~140-
160 kDa), indicating the predominant presence of APP
dimers. However, sAPP complexes in CSF appeared
mainly close to alkaline phosphatase, indicating the in-
stability of the CSF complexes resolved in sucrose gra-
dients containing salt and detergent. Altogether, our
data suggest that different APP complexes are present
in CSF compared to those in the brain.
sAPP heteromers participate in the determination of
sAPPα and sAPPβ by ELISA
The presence of sAPP heteromers in CSF is expected to
affect the determination of sAPPα and sAPPβ by specific
ELISAs. To check this possibility, we analyzed CSF sam-
ples immunoprecipitated with different antibodies to
pull-down potential heteromers. CSF samples from 13
probable AD subjects, characterized for T-tau, P-tau and
Aβ42 levels determined by ELISA kits (Innogenetics,
Figure 3A), and 13 non-disease controls (NDC) were
evaluated. We measured levels of sAPPα and sAPPβ by
two specific ELISAs (the detector antibodies recognize
the C-terminal of sAPPα and sAPPβ respectively, and
their specificity was checked in Additional file 2: Figure
S2). Samples were assayed before and after immunopre-
cipitation by the Sigma-Ct antibody to remove sAPP
forms containing the C-terminal domain (sAPPf), which
is not present in sAPPα or sAPPβ. No differences were de-
tected in sAPPα or sAPPβ levels in either AD or NDC
subjects before immunoprecipitation (Figure 3B). Consist-
ent with other studies, a positive correlation betweensAPPα and sAPPβ was observed in all samples (Additional
file 2: Figure S2, r = 0.901; p < 0.001). After immunopre-
cipitation with Sigma-Ct (Figure 3B), the levels of sAPPα
and sAPPβ in AD and NDC samples decreased compared
to levels before immunoprecipitation (sAPPα: ~33% de-
crease, p = 0.001; sAPPβ: ~27%, p = 0.001). This corrobo-
rates the existence of heteromers containing sAPPf and
sAPPβ, but also of sAPPf and sAPPα.
The interference of sAPP heteromers in the measure-
ment of sAPP levels was also tested using an ELISA kit
for full-length APP, which also detects sAPPα (Novex,
Life Technologies). In this ELISA kit, the detector anti-
body recognizes an epitope located between the β-
secretase and α-secretase cleavage sites, and thus, simi-
larly to the 6E10 antibody, detects sAPPα and sAPPf,
but not sAPPβ. Samples (n = 10 in both the AD and
NDC samples) were analyzed before and after immuno-
precipitation with the IBL-β antibody. Levels of sAPP
(sAPPf and sAPPα) decreased greatly after immunopre-
cipitation with IBL-β in both the AD and NDC groups
(~89% decrease, p = 0.001; Figure 3C).
Taken into account all these results, we demonstrate
that the existence of sAPP as heteromers in CSF contrib-
utes to the estimation of sAPPα and sAPPβ levels by
ELISA.
Levels of sAPPf in AD CSF
Finally, to assess whether sAPPf levels are altered in AD,
we analyzed by Western blotting fresh aliquots of the
same CSF samples previously characterized for classical
biomarkers (see Figure 3A). To prevent interference of
sAPP heteromers, the electrophoresis was performed
under denaturing conditions. sAPPf was detected with
the Covance-Ct antibody (Figure 4A). Immunoreactivity
of the major broad band, ~110 kDa, was not significantly
different in AD compared to NDC subjects (Figure 4B).
The faint 130 kDa band was not detected in all samples.
In some cases where the quantification was possible, the
intensity of the 130 kDa band was quantified and found
to be increased by ~115% in AD (n = 8) compared to
NDC subjects (n = 6; p = 0.02). Interestingly, the levels of
sAPPf correlated with Aβ42 in the AD group (r = 0.739;
p = 0.004), but not in the NDC cases. There was no asso-
ciation of sAPPf levels with age or gender.
Discussion
In this report, we confirm the presence of sAPPf in hu-
man CSF and characterize that sAPP species associate in
heteromeric complexes. Our studies demonstrate that
sAPP heteromers contribute to the estimation of sAPPα
and sAPPβ levels by current standard ELISA methods.
Membrane-associated APP is usually detected as a
group of 110-130 kDa proteins, and sAPPf in human
CSF is expected to have an apparent molecular mass
Figure 3 (See legend on next page.)
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Figure 3 sAPP heteromers contribute to the estimation of sAPPα and sAPPβ levels by ELISA. (A) Box plot of CSF levels of classical AD biomarkers
Aβ42, T-tau and P-tau from 13 NDC controls and 13 probable AD cases. (B) CSF samples were also assayed for specific sAPPα and sAPPβ using ELISA kits
from IBL before (incubated with Sepharose A beads in the absence of an antibody) and after immunoprecipitation (IP) with the Sigma-Ct antibody. Before
immunoprecipitation, no differences were found between NDC and AD subjects. After immunoprecipitation, levels of sAPPα and sAPPβ
reduced significantly in both groups (paired Student-t test). (C) 10 fresh aliquots (from the 13 cases available) from NDC and AD groups
were assayed with an alternative ELISA kit from Novex, of which the detection antibody binds to an epitope present in sAPPα and absent
in sAPPβ, thus recognizing APPα and sAPPf. Before immunoprecipitation, no differences were found between NDC and AD subjects. Immunoprecipitation
significantly reduced the levels of sAPPα and sAPPf in NDC and AD subjects (paired Student-t test). The data represent the means ± SEM (n.s.,
not significant).
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sAPPβ fragments are predicted to be ~5-10 kDa smaller
than full-length APP [5]. These small size differences
make it difficult to distinguish sAPPf from sAPPα or
sAPPβ (see Additional file 1: Figure S1). Moreover, there
are three APP isoforms expressed in the brain resulting
from alternative exon splicing [15]; APP695, the pre-
dominant isoform in neurons consisting of 695 amino
acids, and APP751 and APP770, both isoforms harbor-
ing an amino acid insert homologous to a Kunitz-type
trypsin inhibitor (KPI) [16]. Therefore, the expected
sAPP banding pattern in CSF is very complex, with three
potential variants of each sAPPα and sAPPβ originated
from APP695, 751 and 770 isoforms. Our present study
adds complexity to this scenario, demonstrating that
sAPPf is also present in human CSF.
In our study, no statistical differences were observed
in the level of the broad sAPPf band of 110 kDa (attrib-
utable by its molecular mass to APP695) between prob-
able AD patients and non-demented controls; however,Figure 4 sAPPf immunoreactivity levels in CSF from NDC and AD sub
13 AD subjects. (A) Representative blot of CSF-sAPPf resolved with the Cov
samples, and was quantified at longer exposure than the 100 kDa band. (B
and 130 kDa, from the NDC and AD cases (performed in duplicate). A cont
normalize the immunoreactive signal between immunoblots. Differences w
The data represent the means ± SEM (n.s., not significant).its levels correlated with Aβ42 levels in the AD group;
this may indicate an association with the pathological
levels of Aβ42, and requires further research. The 130 kDa
band (which should correspond to APP751/770) was
found to be increased in AD CSF. Despite the low number
of samples analyzed, and the difficulty in quantifying the
immunoreactivity of the 130 kDa band, our data suggest
that the analysis of KPI-containing sAPPf forms may be of
particular interest and needs to be more specifically ad-
dressed. Interestingly, the proportion of KPI-containing
isoforms appears significantly elevated in the soluble sub-
cellular fraction of AD brains [17].
The origin or functional significance of sAPPf in CSF
is currently not known. Early studies failed to demon-
strate the presence of sAPP isoforms containing its C-
terminal domain in human CSF [4], but later work
suggested that sAPPf exists in this fluid [11], in plasma
[18] and can be released from platelets [18,19], chro-
maffin cells [11,12] and different cell lines [11,20]. In
chromaffin cells, it has also been proposed that sAPPfjects. Immunodetection of sAPPf in CSF samples from 13 NDC and
ance-Ct antibody. The 130 kDa band was not easily visualized in all
) Densitometric quantification of the APP-immunoreactive bands, ~110
rol CSF sample was run on different gels (processed in parallel) to
ere found only for the 130 kDa band between NDC and AD subjects.
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population [12]. In cell culture, the levels of sAPPf are
modulated by cell depolarization in a Ca2+-dependent
manner, as well as by cholinergic receptor agonists and
antagonists [11]. A mechanism for sAPPf to appear in
CSF has yet to be determined, but passive release from
brain cells or neuronal cell death may be possible, as re-
cently observed for BACE1 [21]. Full-length BACE1 and
other membrane resident protein, such as presenilin-1,
are present in CSF [22].
Previous studies indicate that cellular APP may form
high molecular-weight APP complexes [13,23]. Co-
immunoprecipitation and native gel analysis indicated an
interaction among all sAPP forms in CSF, and their as-
sembly into APP heteromeric complexes. This could be
due to the self-association properties of APP by hydropho-
bic and/or ionic interactions resulting in the formation of
heteromeric sAPP complexes which contain several forms
of sAPP, including sAPPf. Thus, CSF heteromers differ
from brain APP membrane-homodimers. Native gel ex-
periments suggest the existence of large sAPP hetero-
mers in CSF. Interestingly, the sAPPf forms released
from platelets are more susceptible to sedimentation by
ultracentrifugation than sAPP forms lacking the carb-
oxyl terminal [18]; this could indicate a different degree
of oligomerization or differences in the conformation of
soluble aggregates compared to cellular dimers. Here, we
observed differences during ultracentrifugation in sucrose
density gradients containing Brij 97 detergent, where APP
complexes from the CSF appear to be more unstable than
brain APP dimers.
The nature and composition of sAPPf oligomers in CSF,
as well the possibility that other proteins could also be
part of the sAPP complexes, have yet to be deciphered.
Based on our co-immunoprecipitation and ELISA ana-
lysis, we assume that all the possible sAPP heteromers are
present in CSF.
Previous reports on the levels of sAPP in CSF draw a
complex scenario. A strong positive correlation between
sAPPα and sAPPβ levels has been consistently found
in healthy elderly individuals and AD subjects in our
and other studies [6,7,9,10,24]. Since the production
of sAPPβ should be inversely proportional to that of
sAPPα, this is an unpredicted finding. The changes in
APP gene expression levels in the brain of AD subjects
are modest [25,26], and do not to explain the concurrent
positive correlation in sAPPα and sAPPβ levels. It has
been suggested that there may be a common factor that
regulates the metabolism of APP by influencing the ac-
tivity of both α- and β-secretases or by a mutual influ-
ence on both secretases [6]. Cross-reactivity between
sAPPα and sAPPβ assays has also been suggested as
a contributing factor for their unexplained correlation
[27]; however, development of assays based on pan-specific antibodies further confirms this positive correl-
ation. Instead, we cannot totally exclude the possibility
that cross-reactivity also contribute in our determination
of sAPP heteromers; although our results indicate that
such a strong correlation may be explained by the pres-
ence of heteromers containing sAPPβ and sAPPα. These
sAPPβ/sAPPα heteromers would contribute proportion-
ally to the determinations of both sAPPα and sAPPβ by
ELISAs, leading to this positive correlation.
In the same line, studies of sAPPα and sAPPβ levels in
CSF likely would reflect potential changes in the balance
between non-amyloidogenic and amyloidogenic pathways,
but reports are also contradictory. Studies of sAPPα levels
in CSF from AD subjects range from an increase
[8,27-29], to no significant change [30-33], or a slight de-
crease [4,34-37], compared to levels in NDC subjects.
Similarly, some reports indicate that sAPPβ levels increase
in AD compared to NDC cases [27], but others show no
change or even a decrease [7,32,35,37]. Simultaneous de-
termination in CSF of sAPPα levels with respect to sAPPβ
could potentially reflect APP brain metabolism, but com-
parative studies have again resulted controversial. Given
that the α-secretase pathway is the predominant APP pro-
cessing pathway, higher levels of sAPPα would be ex-
pected compared to sAPPβ levels in CSF from non-
disease individuals. Some studies have reported higher
levels of CSF sAPPα than sAPPβ in non-disease controls
[11,32], although most published reports do not support
these results [7,10,24,27]. Our results demonstrate that
the presence of sAPPf, detectable by some ELISAs devel-
oped for sAPPα, should be considered a contributing fac-
tor for these contradictory findings. Thus, comparison of
sAPPβ and sAPPα levels by IBL ELISA kits (using specific
anti-APP antibodies which recognize the C-terminal of
sAPPα or sAPPβ) showed higher amounts of sAPPβ in
CSF than that of sAPPα. Nonetheless, comparison of
sAPPβ with those sAPP levels obtained with the Novex
Life kit does not confirm this appreciation. The Novex
Life kit, like other kits based on the 6E10 antibody [11,32],
is based on an antibody recognizing the N-terminal part
of the Aβ peptide for detection, thus binding sAPPf and
sAPPα. The contribution of sAPPf to the estimation of
sAPPα levels will explain discrepancies between the Novex
Life and IBL kits. Altogether, our data suggest that sAPPβ
is more abundant in CSF than sAPPα, and that sAPPf is
the least represented. However, since all those ELISA kits
do not discriminate between homodimers, heterodimers
and large heteromers, an analysis of sAPPα and sAPPβ
under conditions that favor the measurement of sAPP iso-
forms in their monomeric state is warranted to estimate
their correct potential as AD biomarkers.
Finally, we have speculated about the abundance of
sAPP dimers by our ELISA assays, taking into account
that from these data we cannot discriminate sAPP
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Life ELISA analysis after IBL-β immunoprecipitation, we
presumed that the most abundant oligomers include
sAPPβ, probably being sAPPα/sAPPβ, since the oligomers
which have not been pulled-down, sAPPf/sAPPα, sAPPα/
sAPPα and/or sAPPf/sAPPf, constitute altogether ~10% of
the non-immunoprecipitated samples. Immunoprecipi-
tation with the Sigma-Ct antibody followed by ELISA
analysis for sAPPα and sAPPβ (IBL) revealed in both
cases that sAPPf/sAPPα or sAPPf/sAPPβ heteromers
represent ~30% of oligomers that include sAPPα and
sAPPβ. We speculate that the sAPPα/sAPPα, sAPPf/
sAPPf, but also sAPPβ/sAPPβ homodimers, would con-
stitute the least abundant population. In any case, spe-
cific characterization of each sAPP oligomer in CSF,
and potential differences in the AD condition, will re-
quire further research.Conclusions
The use of CSF biomarkers for AD in clinical practice is
challenging due to the high variability in their levels. Such
variability has been partially attributed to different pre-
analytical and analytical procedures between laboratories,
highlighting the need to establish standardized operating
procedures [38,39]. CSF-sAPPα and sAPPβ have been
proposed as promising CSF biomarkers for AD and other
neuropathological conditions [40-45], but have failed to
meet expectations with their often contradictory findings.
We describe that CSF-sAPP forms, including soluble full-
length APP, assemble into oligomers and that heteromers
contribute to the estimation of sAPP levels by ELISAs,
and thus, potentially account for the underestimation of
real sAPP levels. Our finding could explain the contro-
versy about CSF-sAPPα and sAPPβ levels, and may
change how these biomarkers are assessed. These findings
indicate the need to design new assays for CSF-sAPP, with
new conditions to selectively analyze sAPP monomers,
which could unmask pathological differences, and to de-
velop new approaches for sAPP heteromers, which could
reveal new biomarkers.Material and methods
Patients
This study was approved by the ethics committee of
the Miguel Hernandez University and was carried out
in accordance with the Declaration of Helsinki. Lum-
bar CSF samples were obtained from 13 patients with
probable Alzheimer’s disease (AD; 5 men and 8
women, 67 ± 2 years), and 13 healthy volunteers, non-
demented controls (NDC; 5 men and 8 women, 62 ±
3 years) from the Hospital Clinic (Barcelona, Spain).
All AD patients fulfilled the NINCDS-ADRDA criteria
for “probable” AD [46]. Control subjects had no historyor symptoms of neurological or psychiatric disorders or
memory complaints.
Brain extracts
Brain frontal cortex samples (4 NDC cases, 75 ± 7 years;
post-mortem interval 4-8 hours) were obtained from the
UIPA neurological tissue bank (Unidad de Investigación
Proyecto Alzheimer; Madrid, Spain). Samples were solu-
bilized in 20 mM HEPES pH 7.5, 50 mM KCl, 2 mM
EDTA and ultracentrifuged at 300,000 × g for 1 h. The
pellet was homogenized in 0.5% dodecylmaltoside, 20%
glycerol, and 25 mM bis-Tris pH 7.0. After 45 min in
continuous mixing at 4°C followed by ultracentrifugation
at 200,000 × g for 30 min, the supernatant was collected
and frozen at -80°C.
Cell culture
CHO cells over-expressing wild-type human APP-751
[47] were cultured in Opti-MEM supplemented with
10% FBS, G-148 (200 μg/ml) and puromycin (2.5 μg/ml).
Western blotting
Samples of CSF (30 μL) were boiled at 95°C for 5 min
and electrophoresed in 7.5% SDS-PAGE. sAPP species
were detected using the following antibodies: anti-APP
C-terminal (monoclonal, 1:2,000; Covance, Princeton,
NJ, USA; named here Covance-Ct), anti-APP C-terminal
(polyclonal, 1:2,000; Sigma Aldrich, St. Louis, MO, USA;
named here Sigma-Ct), anti-APP 6E10 (which reacts
with both sAPPf and sAPPα, as well as with free Aβ;
monoclonal, 1:2,000; Covance; named here 6E10), anti-
APP N-terminal (polyclonal, 1:2,000; Sigma Aldrich;
named here Sigma-Nt), anti-sAPPβ (specific for the C-
terminus of sAPPβ; polyclonal, 1:50; IBL, Hamburg,
Germany; named here IBL-β), and anti-sAPPα (specific
for the C-terminus of sAPPα; monoclonal, 1:50; IBL;
named here IBL-α). When appropriate, a control CSF
sample was used to normalize the immunoreactive signal
between immunoblots. The signal was visualized by
LuminataTM Forte (Merck-Millipore, Feltham, UK) and
analyzed using Science Lab Image Gauge v4.0 software
(Fujifilm).
To test the specificity of the APP antibodies, aliquots
of conditioned media from CHO cells over-expressing
APP-751 were resolved by simultaneous detection of im-
munoreactivity to two-antibodies (using a different com-
bination of antibodies: Covance-Ct/IBL-β, Sigma-Ct/
6E10 and 6E10/IBL-β). Blots were then probed with the
appropriate conjugated secondary antibodies (IRDye
800CW goat anti-mouse and IRDye 680RD goat anti-
rabbit; LI-COR Biosciences GmbH, Bad Homburg,
Germany) and imaged on an Odyssey Clx Infrared Im-
aging System (LI-COR). Band intensities were analyzed
using LI-COR software (Image Studio Lite).
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The Life Technologies NativePAGE Novex 4-16% Bis-
Tris Gel System was used in accordance with the manu-
facturer’s protocol. Samples were prepared in a 30 μl
total volume containing 7.5 μL of NuPage LDS sample
buffer (4×), 3 μl of 5% G-250 sample additive and 1.5 μl
of DDM 10% (n-dodecyl-β-D-maltoside). The Native-
Mark™ unstained protein standard (Life Technologies,
Carlsbad, CA, USA) was used as a protein ladder.
Immunoprecipitation
Immunoprecipitations were performed at 4°C by incubat-
ing 150 μL of CSF overnight with 120 μL Sepharose A
beads coupled to the specific APP antibody. Precipi-
tated proteins were eluted with 0.1 M glycine buffer at
pH 2.5. Immunoprecipitation controls were performed
in Sepharose A beads, but absent of any antibody. After
pH neutralization with 1 M Tris-HCl pH 9.5, the super-
natants were denatured in Laemmli sample buffer at
95°C for 5 min. Preliminary assays resolved by ELISA
proved the lack of non-specific binding of sAPP to
Sepharose A beads (without an antibody), compared
with aliquots samples assayed directly (not incubated in
the presence of Sepharose A beads or any antibody).
Sucrose gradients
CSF samples and brain extracts were analyzed for APP
complexes by ultracentrifugation at 250,000 × g in a con-
tinuous sucrose density gradient (5-20%). CSF aliquots
(150 μL) and brain extracts (150 μl) were carefully
loaded onto the top of the gradient containing 2 mL of
0.15 M NaCl, 50 mM MgCl2 and 0.5% Brij 97, in
50 mM Tris-HCl (pH 7.4). After centrifugation for 4 hr
at 4°C in a Beckman TLS 55 rotor, approximately 13
fractions were carefully collected from the top of the
tubes. Enzyme markers of known sedimentation coeffi-
cient, β-galactosidase, catalase and alkaline phosphatase
were used.
Measurement of sAPPα and sAPPβ by ELISA
A commercial ELISA kit from IBL (Hamburg, Germany)
was used to quantify sAPPα (#27734) and sAPPβ (#27735)
in CSF. These assays are based on a solid-phase sandwich
ELISA using specific anti-APP antibodies which recognize
the C-terminal of sAPPα and sAPPβ. The manufacturer
estimated that cross-reactivity between sAPPα and sAPPβ
fragments in each kit is less than 1.5%, and that both
assays do not cross-react with full-length APP. A com-
mercial ELISA kit for sAPPf (Novex, Life-Technologies,
Carlsbad, CA, USA, #KHB0051) was also employed. This
assay is based on an N-terminal APP capture-antibody
and an antibody recognizing the N-terminal part of the
Aβ peptide for detection, thus binding sAPPf and sAPPα,
but not sAPPβ.Measurement of T-tau, P-tau and Aβ42 by ELISA
Total tau (T-tau), phosphorylated tau (P-tau) and Aβ1-
42 (Aβ42) in CSF were determined using specific ELISA
(Innogenetics, Ghent, Belgium).Statistical analysis
All data were analyzed using SigmaStat (Version 2.0;
SPSS, Inc.) by a Student’s t test (two-tailed) or a Mann-
Whitney U test for single pairwise comparisons and deter-
mination of exact p values. Results are presented as
means ± SEM. Correlation between variables was assessed
by linear regression analyses. p values < 0.05 were consid-
ered significant.Additional files
Additional file 1: Figure S1. SDS-PAGE analysis and fluorescence
detection of sAPP species. For the analysis of sAPP species, and to probe the
specificity of the anti-APP antibodies, aliquots of conditioned media from
CHO cells over-expressing APP-751 were analyzed by SDS-PAGE and resolved
with two different anti-APP antibodies simultaneously. The fluorescence of
the secondary antibodies (RDye 800CW goat anti-mouse, green; IRDye 680RD
goat anti-rabbit, red) was detected with the Odyssey CLx Infrared Imaging
system (LI-COR). (A) sAPPf was resolved with Covance-Ct and sAPPβ
was resolved with the IBL-β antibody. (B) sAPPf was resolved with
Sigma-Ct and sAPPf and sAPPα were resolved with the 6E10 antibody.
(C) sAPPf and APPα were detected with 6E10 and sAPPβ was resolved
with IBL-β. (D) sAPPα was resolved with the IBL-α antibody and sAPPβ
was resolved with the IBL-β antibody. Simultaneous fluorescence serves
to demonstrate the specificity of the C-terminal, IBL-β and IBL-α antibodies.
Image showing co-localization (yellow) was only evident combining the
C-terminal antibody Sigma-Ct with 6E10, whose epitope, located between
the β-secretase and α-secretase cleavage sites, is present in both sAPPα and
sAPPf.
Additional file 2: Figure S2. Positive correlation between sAPPα and
sAPPβ in CSF samples. CSF samples from 13 NDC (closed circle) and 13 AD
subjects (open circle) were assayed for sAPPα and sAPPβ fragments using
specific ELISA kits (see Figure 3). When data from NDC and AD were
analyzed together, a strong positive correlation between sAPPα and sAPPβ
levels was found (regression line for all the CSF samples is represented by a
solid line; r = 0.901; p < 0.001). This correlation remained significant when
data were analyzed separately for AD subjects (regression line is
represented by a dotted line; r = 0.911, p < 0.001), or NDC subjects
(regression line is not represented; r = 0.896, p < 0.001).
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